Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin E and CVD

This article was originally published in The Tan Sheet

Executive Summary

Natural source vitamin E (400 IU/day) has neutral effect on arterial plaque and other heart disease risk factors, subset study of Heart Outcomes Prevention Evaluation finds. "There were no differences in atherosclerosis progression rates between patients on vitamin E and those on placebo," SECURE study researchers Eva Lonn, MD, McMaster University, Hamilton, Ontario, et al. say in Feb. 20 issue of Circulation. The 732-patient Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E was part of the HOPE trial, which found similar results regarding the nutrient (1"The Tan Sheet" Jan. 24, 2000, p. 11)

You may also be interested in...



Vitamin E Cardiovascular Benefits Disputed In HOPE Study

Long-term daily vitamin E supplementation has no apparent effect on cardiovascular outcomes in high-risk individuals 55 years and older, Heart Outcomes Prevention Evaluation Study (HOPE) investigators report in the Jan. 20 New England Journal of Medicine.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel